+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Efficacy of biorhythmic transdermal combined hormone treatment in relieving climacteric symptoms: a pilot study

Efficacy of biorhythmic transdermal combined hormone treatment in relieving climacteric symptoms: a pilot study

International Journal of General Medicine 4: 159-163

To evaluate the efficacy of a combination of bioidentical combined 17β-estradiol and progesterone transdermal delivery system (lipophilic emulsion-type base) to relieve climacteric symptoms. The hormonal replacement was given during a period of 6 months at four different cyclic doses to mimic the normal ovary secretory pattern. An open, randomized, comparative, between-patient trial conducted over 6 months in 29 menopausal women with climacteric symptoms assessed with the Kupperman index at baseline and during treatments. Saliva and serum values of 17β-estradiol and progesterone were quantitated before treatment and after 3 and 6 months. Pharmacokinetic data following transdermal administration of 17β-estradiol (0.3 mg, daily) and progesterone (100 mg, daily) were calculated from saliva levels using high-performance liquid chromatography analysis. Improvement in climacteric symptoms was reported in 93% of women evaluated before and after 3 and 6 months of treatment. Values of saliva 17β-estradiol increased after 6 months from 0.6 ± 0.3 pg/mL to 14.1 ± 3.3 pg/mL, and the values of serum 17β-estradiol increased from 3.3 ± 2.8 pg/mL to 80.6 ± 21.9 pg/mL. Of responders, 88% characterized symptom relief as complete. No adverse health-related events were attributed to the bioidentical hormone therapy. Time to maximum saliva concentrations (Tmax), in all experimental cases, was observed after 6 hours. Baseline values were reached within 24 hours, indicating a diurnal rhythm of 17β-estradiol seen in normally cyclic women over the 24-hour period, ie, its daily biological rhythm. Percutaneous absorption of 17β-estradiol, as well as the absorption of progesterone, was associated with relief of climacteric symptoms. The cyclical transdermal delivery of combined bioidentical hormones may be advantageous because it mimics the secretory profiles of 17β-estradiol and progesterone in normally cyclic women over a 28-day period. Larger studies are needed to determine the long-term effects of our therapy.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 052900278

Download citation: RISBibTeXText

PMID: 21475623

DOI: 10.2147/ijgm.s16139

Related references

A pilot study comparing the clinical effects of Jia-Wey Shiau-Yau San, a traditional Chinese herbal prescription, and a continuous combined hormone replacement therapy in postmenopausal women with climacteric symptoms. Maturitas 44(1): 55-62, 2003

Nanostructured transdermal hormone replacement therapy for relieving menopausal symptoms: a confocal Raman spectroscopy study. Clinics 69(2): 75-82, 2014

Efficacy on climacteric symptoms and safety of low dose estradiol transdermal matrix patches. A randomized, double-blind placebo-controlled study. Arzneimittel-Forschung 50(3): 293-300, 2000

The efficacy of low estrogen transdermal therapy in climacteric symptoms management. Ginekologia Polska 71(9): 1079-1082, 2000

Efficacy of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopause. American Journal of Obstetrics & Gynecology 182(1 Part 1): 7-12, 2000

Pilot study of hormone replacement therapy and menopausal symptoms, depression, and quality of life in Korean climacteric women. Psychological Reports 98(2): 374-378, 2006

Pilot study of fluvoxamine treatment for climacteric symptoms in Japanese women. Biopsychosocial Medicine 1: 12, 2007

An open, randomized assessment of the efficacy and safety of two transdermal estradiol patches for relief of climacteric symptoms. Maturitas 27(Suppl. ): 209, 1997

Climacteric symptoms. Hormone treatment relieves climacteric symptoms. Vardfacket 15(3): Ix, 1991

Efficacy and tolerability of transdermal 17 beta-estradiol in patients with climacteric symptoms: Dose titration according to individual choice. Current Therapeutic Research 57(7): 506-515, 1996

Effects on climacteric symptoms, bone and lipoprotein metabolism of hormone replacement therapy delivered by estradiol-releasing intravaginal rings: a pilot study. Climacteric 6(3): 211-220, 2003

The treatment of climacteric symptoms using vaginal rectal and transdermal estrogen substitution. Gynaekologe 19(4): 248-253, 1986

Comparison of transdermal and subcutaneous administration of estradiol in the treatment of climacteric symptoms. Nederlands Tijdschrift Voor Geneeskunde 131(50): 2301-2304, 1987

Can transcranial brain-targeted bright light treatment via ear canals be effective in relieving symptoms in seasonal affective disorder? A pilot study. Medical Hypotheses 78(4): 511-515, 2012